Breaking News

Fortitude Biomedicines Launches, Will Advance Treatments for Autoimmune Diseases and Cancer

The company will be focused on immune cell-targeting biologics and molecular glue payload-enabled antibody-drug conjugates.

Author Image

By: Patrick Lavery

Content Marketing Editor

Fortitude Biomedicines has launched following closing of $13 million in seed financing. Based in Waltham, Mass., the biopharmaceutical company specializes in immune cell-targeting biologics and molecular glue payload-enabled antibody-drug conjugates (ADCs). Those treatments, according to the company, address a wide range of autoimmune diseases and cancers. Partners in Fortitude Biomedicines Launch K2 Bio Partners, Shanghai Healthcare Angel Capital, and Elikon Venture co-led the funding....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters